It would have been interesting to have sat in on the senior management meetings at Merck that thrashed out the Organon ...

Jennifer Halchak; VP, IR; Organon & Co. Kevin Ali; Chief Executive Officer, Director; Organon & Co. Matthew Walsh; Chief Financial Officer, Senior Vice President; Or ...

This news release contains certain forward-looking statements relating to BAT8006, BAT8008, BAT8010, BAT1006, BAT1308 or the product pipelines in general of Bio-Thera Solutions. Readers are ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

In another development, Organon has acquired the U.S. rights to TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen, further expanding its arthritis treatment portfolio. Furthermore, Biogen plans to ...

At the top of April, Organon announced the acquisition of Tofidence (tocilizumab-bavi), a biosimilar approved by the FDA in October 2023 for the treatment of rheumatoid arthritis, giant cell arteritis ...